Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Novel SERD, LSZ102, shows promise for pretreated ER+ breast cancer
- Author:
- Sharon Worcester
LSZ102 was relatively well tolerated as a single agent and in combination with ribociclib and alperisib.
News
Tumor markers are ‘valuable’ for relapse detection in rare CNS tumors
- Author:
- Sharon Worcester
Among evaluable patients, 92% of relapses were detectable by tumor markers.
News
Sequential chemoradiation improves DFS in early-stage cervical cancer
- Author:
- Sharon Worcester
The 3-year disease-free survival rate was significantly higher among patients who received sequential chemoradiation than among patients who...
News
Immunotherapy combo improves ORR, PFS in PD-L1+ NSCLC
- Author:
- Sharon Worcester
Adding tiragolumab to atezolizumab led to “clinically meaningful” improvements in patients with PD-L1–positive non–small cell lung cancer.
News
No OS benefit with gefitinib vs. chemo for EGFR+ NSCLC
- Author:
- Sharon Worcester
Adjuvant gefitinib improved disease-free survival, but not overall survival, when compared with standard chemotherapy.
News

Addressing racism, bias in the American maternal mortality crisis
- Author:
- Sharon Worcester
“I think the most important thing you can do is really consider a patient a partner in the care you give them.”
News
Poziotinib provides ‘modest but meaningful’ efficacy in NSCLC subgroup
- Author:
- Sharon Worcester
About 15% of patients achieved a response with poziotinib and 65% had a decrease in tumor size.
News
ALTERNATE trial: No fulvestrant benefit in locally advanced ER+ HER2– breast cancer
- Author:
- Sharon Worcester
The endocrine-sensitive disease rate was similar whether patients received anastrozole alone, fulvestrant alone, or fulvestrant plus anastrozole...
News
LOTUS: Ipatasertib plus paclitaxel may prolong OS in TNBC
- Author:
- Sharon Worcester
Ipatasertib provided a “clinically meaningful,” but not statistically significant, 9-month improvement in median overall survival.
News
Novel penclomedine shows promise for some AYAs with CNS cancers
- Author:
- Sharon Worcester
Two patients who responded to the treatment were in their 59th month of survival at last follow-up.
News
Universal CAR-T therapy produces CRs in relapsed/refractory T-ALL
- Author:
- Sharon Worcester
All five patients studied achieved a complete response, though one patient had a morphological relapse.
News
MRD surveillance can detect relapse before imaging in early-stage NSCLC
- Author:
- Sharon Worcester
Relapse occurred in 9 of 10 patients who were positive for minimal residual disease but had no evidence of relapse on imaging.
News

Vaccine maintenance improves relapse-free survival in BRCA wild-type ovarian cancer
- Author:
- Sharon Worcester
Maintenance therapy with gemogenovatucel-T improved relapse-free survival in patients with wild-type BRCA but...
News

The American maternal mortality crisis: The role of racism and bias
- Author:
- Sharon Worcester
Not only do health care providers need to face their implicit biases, the health care system needs to change.
News
Adding a blood test to standard screening may improve early cancer detection
- Author:
- Sharon Worcester
The blood test detected cancers in seven organs for which no standard screening test is available.